Do analysts prefer ALVR or SPRC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ALVR or SPRC?

SciSparc has higher revenue and earnings than AlloVir. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A SciSparc $856K 5.37 -$12.18M N/A N/A

Is ALVR or SPRC more profitable?

SciSparc's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% SciSparc N/A N/A N/A

Do analysts rate CELU or SPRC?

Celularity presently has a consensus target price of $6.00, suggesting a potential upside of 655.67%. Given Celularity's stronger consensus rating and higher possible upside, equities analysts plainly believe Celularity is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CELU or SPRC?

SciSparc has lower revenue, but higher earnings than Celularity. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celularity $26.55M 0.87 -$91.72M -$3.33 N/A SciSparc $856K 5.37 -$12.18M N/A N/A

Is CELU or SPRC more profitable?

SciSparc has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% SciSparc N/A N/A N/A

Do analysts prefer SPRC or KZIA?

Novogen has a consensus target price of $23.75, suggesting a potential upside of 71.98%. Given Novogen's stronger consensus rating and higher probable upside, analysts clearly believe Novogen is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has preferable valuation & earnings, SPRC or KZIA?

SciSparc has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $856K 5.37 -$12.18M N/A N/A Novogen $30K 759.55 -$13.41M N/A N/A

Is SPRC or KZIA more profitable?

Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A Novogen N/A N/A N/A

Does the media prefer SPRC or KZIA?

In the previous week, SciSparc and SciSparc both had 3 articles in the media. Novogen's average media sentiment score of 0.96 beat SciSparc's score of 0.96 indicating that Novogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SciSparc 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CLRB or SPRC?

Cellectar Biosciences presently has a consensus target price of $11.00, indicating a potential upside of 367.09%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CLRB or SPRC?

SciSparc has higher revenue and earnings than Cellectar Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A SciSparc $856K 5.37 -$12.18M N/A N/A

Is CLRB or SPRC more profitable?

SciSparc's return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% SciSparc N/A N/A N/A

Do analysts recommend TPST or SPRC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, TPST or SPRC?

SciSparc has higher revenue and earnings than Tempest Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A SciSparc $856K 5.37 -$12.18M N/A N/A

Is TPST or SPRC more profitable?

SciSparc's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% SciSparc N/A N/A N/A

SciSparc (SPRC) Competitors

$8.12 -0.43 (-5.03%)

As of 02:59 PM Eastern

Compare

SPRC vs. ALVR, CELU, KZIA, CLRB, and TPST

Should you buy SciSparc stock or one of its competitors? MarketBeat compares SciSparc with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SciSparc include AlloVir (ALVR), Celularity (CELU), Novogen (KZIA), Cellectar Biosciences (CLRB), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical products" industry.

How does SciSparc compare to AlloVir?

AlloVir (NASDAQ:ALVR) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 1.5% of SciSparc shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market.

In the previous week, SciSparc had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for SciSparc and 0 mentions for AlloVir. SciSparc's average media sentiment score of 0.96 beat AlloVir's score of 0.00 indicating that SciSparc is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
SciSparc	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SciSparc's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
SciSparc	N/A	N/A	N/A

SciSparc has higher revenue and earnings than AlloVir.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
SciSparc	$856K	5.37	-$12.18M	N/A	N/A

Summary

SciSparc beats AlloVir on 8 of the 10 factors compared between the two stocks.

How does SciSparc compare to Celularity?

Celularity (NASDAQ:CELU) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Celularity presently has a consensus target price of $6.00, suggesting a potential upside of 655.67%. Given Celularity's stronger consensus rating and higher possible upside, equities analysts plainly believe Celularity is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SciSparc has lower revenue, but higher earnings than Celularity.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.87	-$91.72M	-$3.33	N/A
SciSparc	$856K	5.37	-$12.18M	N/A	N/A

In the previous week, SciSparc had 2 more articles in the media than Celularity. MarketBeat recorded 3 mentions for SciSparc and 1 mentions for Celularity. Celularity's average media sentiment score of 1.89 beat SciSparc's score of 0.96 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Very Positive
SciSparc	Positive

Celularity has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market.

SciSparc has a net margin of 0.00% compared to Celularity's net margin of -345.45%.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
SciSparc	N/A	N/A	N/A

19.0% of Celularity shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 17.3% of Celularity shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

SciSparc beats Celularity on 7 of the 13 factors compared between the two stocks.

How does SciSparc compare to Novogen?

SciSparc (NASDAQ:SPRC) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Novogen has a consensus target price of $23.75, suggesting a potential upside of 71.98%. Given Novogen's stronger consensus rating and higher probable upside, analysts clearly believe Novogen is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Novogen	N/A	N/A	N/A

SciSparc has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market. Comparatively, Novogen has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market.

25.1% of SciSparc shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 1.5% of SciSparc shares are held by company insiders. Comparatively, 1.0% of Novogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SciSparc has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$856K	5.37	-$12.18M	N/A	N/A
Novogen	$30K	759.55	-$13.41M	N/A	N/A

In the previous week, SciSparc and SciSparc both had 3 articles in the media. Novogen's average media sentiment score of 0.96 beat SciSparc's score of 0.96 indicating that Novogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SciSparc	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novogen beats SciSparc on 6 of the 10 factors compared between the two stocks.

How does SciSparc compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

SciSparc has higher revenue and earnings than Cellectar Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
SciSparc	$856K	5.37	-$12.18M	N/A	N/A

In the previous week, SciSparc had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for SciSparc and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.43 beat SciSparc's score of 0.96 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Positive
SciSparc	Positive

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by company insiders. Comparatively, 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cellectar Biosciences presently has a consensus target price of $11.00, indicating a potential upside of 367.09%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SciSparc's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
SciSparc	N/A	N/A	N/A

Cellectar Biosciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market.

Summary

SciSparc beats Cellectar Biosciences on 7 of the 12 factors compared between the two stocks.

How does SciSparc compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

SciSparc has higher revenue and earnings than Tempest Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
SciSparc	$856K	5.37	-$12.18M	N/A	N/A

Tempest Therapeutics has a beta of -1.85, indicating that its stock price is 285% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, SciSparc had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 3 mentions for SciSparc and 1 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.87 beat SciSparc's score of 0.96 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Very Positive
SciSparc	Positive

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 36.3% of Tempest Therapeutics shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SciSparc's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
SciSparc	N/A	N/A	N/A

Summary

SciSparc beats Tempest Therapeutics on 7 of the 10 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRC vs. The Competition

Export

Metric	SciSparc	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.60M	$2.98B	$6.48B	$12.36B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	N/A	18.53	23.95	24.60
Price / Sales	5.37	461.29	536.37	171.61
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	0.63	4.00	10.44	6.77
Net Income	-$12.18M	$75.79M	$3.56B	$337.32M
7 Day Performance	-22.07%	1.96%	0.83%	2.06%
1 Month Performance	68.46%	-0.35%	1.78%	3.93%
1 Year Performance	-86.62%	23.23%	25.59%	32.29%

SciSparc Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRC SciSparc	0.4757 of 5 stars	$8.12 -5.0%	N/A	-85.9%	$4.60M	$856K	N/A	4	Gap Up
ALVR AlloVir	N/A	$4.09 -2.0%	N/A	+64.0%	$20.60M	N/A	N/A	110	High Trading Volume
CELU Celularity	2.83 of 5 stars	$0.77 +12.4%	$6.00 +675.6%	-59.3%	$19.93M	$26.55M	N/A	220	Positive News Gap Up
KZIA Novogen	2.2325 of 5 stars	$11.50 +0.7%	$21.00 +82.6%	+53.5%	$18.88M	$30K	N/A	12
CLRB Cellectar Biosciences	4.4095 of 5 stars	$2.26 -4.2%	$11.00 +386.7%	-82.0%	$18.86M	N/A	N/A	10	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRC) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SciSparc (SPRC) Competitors